Evidence map›Paper›PMID 36995284›Full record

ArticleThe Journal of cell biology2023

A PI3K-calcium-Nox axis primes leukocyte Nrf2 to boost immune resilience and limit collateral damage.

Giuliana D Clemente, Helen Weavers

Open access · hybridAbstract read
In one paragraph

Article in The Journal of cell biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Chiral FeBioactive materials · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Biological resilience in health and disease.Disease models & mechanisms · 2024
    Review
  6. Review
  7. Macrophage Nrf 2 the rescue.The Journal of cell biology · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Giuliana D ClementeSchool of Biochemistry, Biomedical Sciences, University of Bristol , Bristol, UK.ORCID 0000-0002-3130-3800
Helen WeaversSchool of Biochemistry, Biomedical Sciences, University of Bristol , Bristol, UK.ORCID 0000-0002-5383-6085
University of Bristol · GB

Funding

Wellcome TrustWellcome Trust 208762/Z/17/Z
6 · The paper itself

Abstract

Phagosomal reactive oxygen species (ROS) are strategically employed by leukocytes to kill internalized pathogens and degrade cellular debris. Nevertheless, uncontrolled oxidant bursts could cause serious collateral damage to phagocytes or other host tissues, potentially accelerating aging and compromising host viability. Immune cells must, therefore, activate robust self-protective programs to mitigate these undesired effects, and yet allow crucial cellular redox signaling. Here, we dissect in vivo the molecular nature of these self-protective pathways, their precise mode of activation, and physiological effects. We reveal Drosophila embryonic macrophages activate the redox-sensitive transcription factor Nrf2 upon corpse engulfment during immune surveillance, downstream of calcium- and PI3K-dependent ROS release by phagosomal Nox. By transcriptionally activating the antioxidant response, Nrf2 not only curbs oxidative damage but preserves vital immune functions (including inflammatory migration) and delays the acquisition of senescence-like features. Strikingly, macrophage Nrf2 also acts non-autonomously to limit ROS-induced collateral damage to surrounding tissues. Cytoprotective strategies may thus offer powerful therapeutic opportunities for alleviating inflammatory or age-related diseases.

Indexed as

CalciumMacrophagesNF-E2-Related Factor 2Phosphatidylinositol 3-KinasesAnimalsDrosophilaLeukocytesOxidation-ReductionOxidative StressPhagosomesReactive Oxygen SpeciesCalciumNF-E2-Related Factor 2Phosphatidylinositol 3-KinasesReactive Oxygen Species

Identifiers

PMID36995284
PMCPMC10067972
OpenAlexW4361279186

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.